Low Dose Naltrexone & Multipl Sclerosis

Featured Article: Serum [Met(5)]-enkephalin levels are reduced in multiple sclerosis and restored by low-dose naltrexone.

 

Low dose naltrexone in multiple sclerosis: Effects on medication use. A quasi-experimental study.

 

Long-term treatment with low dose naltrexone maintains stable health in patients with multiple sclerosis.

 

Low Dose Naltrexone for Treatment of Multiple Sclerosis: A Retrospective Chart Review of Safety and Tolerability.

 

Pilot trial of low-dose naltrexone and quality of life in multiple sclerosis.

 

Low dose naltrexone therapy in multiple sclerosis.

 

A pilot trial of low-dose naltrexone in primary progressive multiple sclerosis.

 

Ethical Considerations of Patient-Funded Research for Multiple Sclerosis Therapeutics.

 

The effect of low-dose naltrexone on quality of life of patients with multiple sclerosis: a randomized placebo-controlled trial.

 

Opioid growth factor and low-dose naltrexone impair central nervous system infiltration by CD4 + T lymphocytes in established experimental autoimmune encephalomyelitis, a model of multiple sclerosis.

 

Featured Article: Modulation of the OGF-OGFr pathway alters cytokine profiles in experimental autoimmune encephalomyelitis and multiple sclerosis.

 

Low-dose naltrexone for multiple sclerosis and autism: does its benefit reveal a common cause?

 

Intermittent blockade of OGFr and treatment of autoimmune disorders.

 

Experimental autoimmune encephalopathy (EAE)-induced hippocampal neuroinflammation and memory deficits are prevented with the non-opioid TLR2/TLR4 antagonist (+)-naltrexone.

 

Low-dose naltrexone for treatment of multiple sclerosis: clinical trials are needed.

 

Prevention and diminished expression of experimental autoimmune encephalomyelitis by low dose naltrexone (LDN) or opioid growth factor (OGF) for an extended period: Therapeutic implications for multiple sclerosis.

 

Endogenous opioids regulate expression of experimental autoimmune encephalomyelitis: a new paradigm for the treatment of multiple sclerosis.